Although the specific functional mechanism(s) contributing to the increased therapeutic efficacy of dual FASN/HER2 blockade in HER2+ GC remain to be clearly elucidated, thus representing a limitation of this study, our present data demonstrated that targeting FASN in HER2+ GC may be a novel strategy to benefit patients with T resistance. Here, ERBB2 is linked to gastric cancer.